Premium
Resection of small, residual retroperitoneal masses after chemotherapy for nonseminomatous testicular cancer
Author(s) -
Steyerberg Ewout W.,
Marshall Phillip B.,
Jan Keizer H.,
Habbema J. Dik F.
Publication year - 1999
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/(sici)1097-0142(19990315)85:6<1331::aid-cncr16>3.0.co;2-i
Subject(s) - medicine , testicular cancer , malignancy , residual , teratoma , cancer , chemotherapy , resection , surgery , radiology , algorithm , computer science
BACKGROUND After chemotherapy for metastatic, nonseminomatous testicular cancer, small, retroperitoneal lymph nodes still harbor mature teratoma or viable cancer cells in less than half of patients with normal tumor markers. Surgical resection is an effective treatment to remove residual masses, but observation may also be considered. METHODS Using a decision analysis model, the authors estimated the survival achieved with either resection or observation for patients with residual masses measuring 0–20 mm. Prognostic estimates were obtained from an international data set containing 362 patients with masses ≤20 mm and from 10 clinical experts. RESULTS According to the model, resection prolonged life expectancy by more than 2 years for masses 11–20 mm and by more than 1 year for masses 0–10 mm. The estimated gains in 5‐year survival were 4.3% and 2.7%, respectively. In a sensitivity analysis, these results appeared rather robust for changes in the estimates of the experts. The magnitude of the gain in survival, however, depended on the probabilities of the residual histologies, which could be estimated with several well‐known predictors, and the assumed benefit of resection for residual mature teratoma or cancer. CONCLUSIONS Resection may on average be beneficial for patients with small, residual masses. The expected benefit depends on the probability and risks of residual malignancy, regarding which further research is required. For decision‐making regarding individual patients, the morbidity and costs of resection and a patient's individual preferences should be considered in addition to any assumed gain in survival. Cancer 1999;85:1331–41. © 1999 American Cancer Society.